Announcements
- Rezolute to Participate in the Jefferies Global Healthcare Conference
- Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)
- Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
- Phase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual Meeting
- Rezolute Reports Validation of the Potential Use of RZ358 for Treatment of Non-Islet Cell Tumor Hypoglycemia (NICTH)
- Rezolute Reports Second Quarter Fiscal 2024 Results and Provides Business Update
- Rezolute Expands Leadership Team with Appointment of Daron Evans, MS, MBA, as Chief Financial Officer
- Rezolute Receives Innovation Passport Designation from the U.K. Innovative Licensing and Access Pathway Steering Group for RZ358 in the Treatment of Hypoglycemia Due to Congenital Hyperinsulinism
- Rezolute Initiates Phase 3 Clinical Study for RZ358 in Congenital Hyperinsulinism
- Rezolute Completes Enrollment of its Phase 2 Study in Diabetic Macular Edema (“DME”)
More ▼
Key statistics
On Wednesday, Rezolute Inc (6HV1:BER) closed at 3.34, -30.42% below its 52-week high of 4.80, set on May 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 3.34 |
Average volume | -- |
---|---|
Shares outstanding | 40.14m |
Free float | 31.95m |
P/E (TTM) | -- |
Market cap | 232.38m USD |
EPS (TTM) | -1.14 USD |
Data delayed at least 15 minutes, as of May 22 2024 13:10 BST.
More ▼